Inhibikase Therapeutics, Inc. (IKT)

Over the past six months, Inhibikase Therapeutics announced a $100 million and a $115 million public offering of common stock and pre-funded warrants. The company announced its full-year 2025 financial results, including a net loss of $48.3 million. Inducement grants were announced under Nasdaq Listing Rule 5635(c)(4). The first patient was enrolled in the IMPROVE-PAH Global Phase 3 Study of IKT-001. Bank of America and LADENBURG THALM/SH SH initiated coverage with "buy" ratings, while Weiss Ratings reissued a "sell (d-)" rating, and Lifesci Capital upgraded the company to a "strong-buy" rating. The stock's 52-week range has been between $1.33 and $2.27.

Information regarding the specific demand seasonality for Inhibikase Therapeutics' products and services is not readily available. The demand for their pharmaceutical products is likely driven by medical needs rather than seasonal consumer trends.

Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company focused on developing therapeutics for cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH), and treatments for Parkinson's Disease (PD) and related neurological disorders. Their major product candidates include IKT-001, an oral prodrug for PAH currently in Phase 3 clinical trials, and IkT-148009, a small molecule inhibitor for PD. The company also has research programs for other neurological diseases and preclinical development of IkT-001Pro for blood and stomach cancers.

Inhibikase Therapeutics is headquartered in Wilmington, Delaware, with additional offices in Boston, Massachusetts. They collaborate with several U.S. universities for research and development. The global Phase 3 clinical trial for IKT-001 is expected to be conducted in approximately 180 sites worldwide.

Inhibikase Therapeutics has a consensus "Buy" rating from analysts, with an average rating score of 3.13. The average 12-month target price among brokers is $5.50. Positive events contributing to its reputation include the enrollment of the first patient in its global Phase 3 study for IKT-001 in PAH and positive analyst coverage. While there are analyst ratings that are "sell" or "hold," the overall consensus is positive.

As of May 6, 2026, Inhibikase Therapeutics has 86 institutional owners and shareholders holding a total of 110,500,331 shares, with major holders including Sands Capital Ventures, LLC, and Vanguard Group Inc. Individual investors possess the largest stake in the company, holding 39% of the shares. Institutional ownership is approximately 3.81% to 30% of the stock, while hedge funds own about 11%. Insiders collectively own approximately US$7.9 million worth of the company's shares, representing 7.30% of the stock.